Introduction: Diabetes is the most common cause of end-stage renal disease in most parts ofrnthe world. Kidney involvement both directly and indirectly increases involvement of otherrnorgans and increase morbidity and mortality in diabetic patients. However, little is knownrnconcerning when nephropathy develops once a person diagnosed with diabetes. Objective: Thernaim of this study is to determine time to nephropathy and its predictors among type 2 diabeticrnpatient attending at Tikur Anbessa Specialized Hospital, 2019. Methods and materials:rnRetrospective cohort study was employed among Type 2 diabetic patients attending their followrnup at Tikur Anbessa Specialized Hospital from January 1, 2009 to December 31, 2018. KaplanMeierrnmethodrnwasrnusedrntorndeterminerntimerntornnephropathyrnandrnlogrnrankrntestrnwasrnusedrntorncomparernrntimernrnto nephropathy among different covariates in type 2 Diabetes Mellitus patients. Coxrnproportional hazard model was used to identify factors contributing to nephropathy in type 2rndiabetic mellitus patients. Result: The overall incidence rate of diabetic nephropathy amongrnnewly diagnosed type 2 diabetes was found to be 30.4 per 10,000 person-months follow up. Thernmedian time to develop nephropathy was 100.03 months (95% CI, 96.7 â€“ 107). Predictors ofrnnephropathy were being male [HR: 2.7 95%CI; 1.39, 5.23], duration of diabetes [HR:rn1.003,95% CI;1.001,1.006], hemoglobin A1c [HR: 1.74, 95% CI; 1.67,3.12], fasting bloodrnsugar [HR: 1.12, 95% CI; 1.03,1.97]. Whereas, high density lipoprotein greater than 40mg/dlrn[HR: 0.37, 95% CI; 0.16, 0.83] and both oral and injection therapy [HR: 0.07, 95% CI; 0.01,rn0.59], were reduced the hazard of nephropathy. Conclusion: In this study, the incidence ofrndiabetic nephropathy among type 2 DM patients was relatively high and which is becoming thernraising national burden. Being male, longer duration of diabetes, hemoglobin A1c, and one unitrnincreasing of fasting blood sugar were increase the hazard of diabetic nephropathy. On therncontrary high density lipoprotein greater than 40mg/dl and those diabetic clients who hadrnreceived oral and injection therapy were reduced the hazard of diabetic nephropathy.